NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
63459-0912-12 | 63459-0912 | tbo-filgrastim | Granix | 480.0 ug/.8mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Nov 11, 2013 | In Use | |
00069-0324-01 | 00069-0324 | Pegfilgrastim-apgf | NYVEPRIA | 6.0 mg/.6mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Dec 15, 2020 | In Use | |
62756-0452-37 | 62756-0452 | Octreotide acetate | BYNFEZIA Pen | 2.5 mg/mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Feb 24, 2025 | In Use | ||
85043-0025-02 | 85043-0025 | Leuprolide acetate | Vabrinty | 22.5 mg/.375mL | Hormonal Therapy | GnRH Agonist | Subcutaneous | Aug 4, 2025 | In Use | ||
00069-2522-02 | 00069-2522 | Elranatamab-bcmm | Elrexfio | 44.0 mg/1.1mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Subcutaneous | Aug 15, 2023 | In Use | |
61314-0240-63 | 61314-0240 | Denosumab | JUBBONTI | 60.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 2, 2025 | In Use | |
61314-0228-94 | 61314-0228 | Denosumab | WYOST | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 2, 2025 | In Use | |
62935-0223-05 | 62935-0223 | Leuprolide Acetate | Eligard | Hormonal Therapy | GnRH Agonist | Subcutaneous | Aug 26, 2002 | In Use | |||
69097-0870-67 | 69097-0870 | Lanreotide acetate | Lanreotide Acetate | 120.0 mg/.5mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Dec 24, 2021 | In Use | ||
00004-0350-39 | 00004-0350 | Peginterferon alfa-2a | Pegasys | 180.0 ug/mL | Immunotherapy | Cytokine | Interferon | Subcutaneous | Oct 16, 2002 | Sep 1, 2009 | No Longer Used |
62935-0303-30 | 62935-0303 | Leuprolide Acetate | Eligard | Hormonal Therapy | GnRH Agonist | Subcutaneous | Feb 26, 2003 | In Use | |||
00004-0357-99 | 00004-0357 | Peginterferon alfa-2a | Pegasys | 180.0 ug/.5mL | Immunotherapy | Cytokine | Interferon | Subcutaneous | Aug 22, 2011 | Sep 19, 2014 | No Longer Used |
57894-0470-01 | 57894-0470 | Talquetamab | TALVEY | 40.0 mg/mL | Immunotherapy | T Cell Receptor (TCR) | GPRC5D, CD3 | Subcutaneous | Aug 9, 2023 | In Use | |
63459-0912-36 | 63459-0912 | tbo-filgrastim | Granix | 480.0 ug/.8mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Mar 2, 2015 | In Use | |
59572-0775-01 | 59572-0775 | Luspatercept | Reblozyl | 75.0 mg/1 | Immunotherapy | Erythropoiesis-Stimulating Agent | Subcutaneous | Nov 8, 2019 | In Use | ||
62935-0452-45 | 62935-0452 | Leuprolide Acetate | Eligard | Hormonal Therapy | GnRH Agonist | Subcutaneous | Jan 23, 2002 | Apr 26, 2019 | No Longer Used | ||
70121-1694-02 | 70121-1694 | Plerixafor | Plerixafor | 24.0 mg/1.2mL | Ancillary Therapy | Immunostimulant | Stem Cell Mobilizer | Subcutaneous | Jul 25, 2023 | In Use | |
50242-0108-86 | 50242-0108 | Rituximab and hyaluronidase | Rituxan Hycela | 2000.0 U/mL, 2000.0 U/mL, 120.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Subcutaneous | Jun 23, 2017 | In Use | |
72843-0591-99 | 72843-0591 | Leuprolide acetate | Leuprolide acetate | 5.0 mg/ml | Hormonal Therapy | GnRH Agonist | Subcutaneous | Oct 25, 2024 | In Use | ||
76961-0101-01 | 76961-0101 | Eflapegrastim-xnst | Rolvedon | 13.2 mg/.6mL | Ancillary Therapy | Immunostimulant | Granulocyte colony stimulating factor | Subcutaneous | Oct 18, 2022 | In Use | |
15054-1090-04 | 15054-1090 | Lanreotide acetate | Somatuline Depot | 90.0 mg/.3mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Sep 1, 2019 | In Use | ||
00310-0951-30 | 00310-0951 | Goserelin acetate | Zoladex | 10.8 mg/1 | Hormonal Therapy | GnRH Agonist | Subcutaneous | May 5, 2003 | Mar 31, 2020 | No Longer Used | |
67457-0833-06 | 67457-0833 | Pegfilgrastim | Fulphila | 6.0 mg/.6mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Jul 9, 2018 | May 31, 2026 | In Use |
55150-0356-01 | 55150-0356 | Plerixafor | Plerixafor | 24.0 mg/1.2mL | Ancillary Therapy | Immunostimulant | Stem Cell Mobilizer | Subcutaneous | Jul 24, 2023 | In Use | |
61314-0866-01 | 61314-0866 | Pegfilgrastim-bmez | ZIEXTENZO | 6.0 mg/.6mL | Ancillary Therapy | Immunostimulant | Colony-Stimulating Factor | Subcutaneous | Nov 4, 2019 | Feb 28, 2026 | In Use |
Found 11765 results — Export these results